Opus Genetics reports Q3 2026 results, multiple IRD gene therapy milestones
Cohort 2 dosing wraps in the BEST1 program, the LCA5 Phase 3 trial is fully enrolled, and an RDH12 IND clearance adds a third clinical-stage gene therapy as cash runway extends into 2029.
SEC filing